Abstract
Hyperuricemia is a clinical important problem and its prevalence has been increased. Latest topics are described. The guideline adequately managing gout was published from American College of Rheumatology (ACR). Various optimal uses of urate-lowering therapy (ULT) were presented. The cardiorenal effects of hyperuricemia have been investigated for years. Regarding the patients on chronic kidney disease (CKD) and high risk of progression, ULT with allopurinol did not show the decline in eGFR compared to the control. Recently, dotinurad that is a new selective urate reabsorption inhibitor (SURI) would be applied to medical practice. Low-dose dotinurad showed satisfactory pharmacological efficacy.
Highlights
The prescription number has increased 20-fold for 7 years, when the data of prescription was possible. These situations suggest the necessity of aggressive target-driven treatment for controlling hyperuricemia and gout [2]
Mini Review topics are described for i) the latest guidelines, ii) the cardiorenal effects of gout and hyperuricemia and iii) uric acid-lowering drugs
Progression and/or chronic kidney disease (CKD), urate-lowering therapy (ULT) by providing allopurinol has not brought the reduction of eGFR in comparison with the control
Summary
Provided prescriptions of allopurinol and colchicine have increased by 165.6% and 71.4%, respectively during this period. Mini Review topics are described for i) the latest guidelines, ii) the cardiorenal effects of gout and hyperuricemia and iii) uric acid-lowering drugs. Progression and/or CKD, ULT by providing allopurinol has not brought the reduction of eGFR in comparison with the control.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
